Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ACR-2316

Small molecule · Inhibitor of Wee1 and PKMYT1 · developed by Acrivon Therapeutics

Phase 1/2 Most advanced trial

ACRV Developer

1 Registered trials

What is ACR-2316?

ACR-2316 is an orally bioavailable small-molecule inhibitor of the tyrosine kinases Wee1 and PKMYT1. By inhibiting these kinases, it prevents CDK1 and CDK2 phosphorylation, promoting premature mitosis and mitotic arrest while allowing accumulation of unrepaired DNA damage and apoptosis in tumor cells. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: Wee1, PKMYT1
Mechanism: Inhibitor of Wee1 and PKMYT1
Pathways: cell cycle progression, G2/M checkpoint, DNA damage response, apoptosis
Therapy area: Oncology
Developer: Acrivon Therapeutics (ACRV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06667141	Phase 1/2	Specific Advanced Solid Tumors	Recruiting	ACRV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Specific Advanced Solid Tumors

Other drugs acting on WEE1 / PKMYT1

Adavosertib Phase 2 APR-1051 Phase 1 Potrasertib Investigational

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACRV page.

Follow ACRV, the company behind ACR-2316

See ACRV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACRV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z